Lists of people executed in the United States

Access Brand Management’s Innovative Business Model Builds Global Brands with Customer Evangelists that Drive Sales and Growth in a Non-traditional Way

Retrieved on: 
Wednesday, August 17, 2022 - 11:51pm

What TikTok did for social sharing, Access Brand Management (ABM) is doing for brands and products.

Key Points: 
  • What TikTok did for social sharing, Access Brand Management (ABM) is doing for brands and products.
  • ABMs insight: The world is awash in great products and brands that never see their way to market.
  • Founded in 2017, award-winning Access Corporate Group is an innovative, comprehensive brand management company with a global business ecosystem that ensures end-to-end connection between brands and consumers.
  • Access is founded by entrepreneurs for entrepreneurs, with a mission is to become one of the top ten brand management companies, globally.

Sanfilippo Syndrome Epidemiology Forecast Report 2019-2022 & 2032 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 17, 2022 - 1:56pm

The "Sanfilippo Syndrome - Epidemiology Forecast to 2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Sanfilippo Syndrome - Epidemiology Forecast to 2032" report has been added to ResearchAndMarkets.com's offering.
  • This "Sanfilippo Syndrome - Epidemiology Forecast to 2032" report delivers an in-depth understanding of the disease, historical and forecasted Sanfilippo Syndrome epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • The Sanfilippo Syndrome epidemiology covered in the report provides historical as well as forecasted Sanfilippo Syndrome epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.
  • The Sanfilippo Syndrome report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
    The Sanfilippo Syndrome Epidemiology Report and Model provide an overview of the global trends of Sanfilippo Syndrome in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
    The report provides insight into the historical and forecasted patient pool of Sanfilippo Syndrome in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan

Febrile Neutropenia Epidemiology Forecast/Analysis Report 2019-2022 & 2032 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 17, 2022 - 1:39pm

This "Febrile Neutropenia - Epidemiology Forecast to 2032" report delivers an in-depth understanding of the disease, historical and forecasted Febrile Neutropenia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Key Points: 
  • This "Febrile Neutropenia - Epidemiology Forecast to 2032" report delivers an in-depth understanding of the disease, historical and forecasted Febrile Neutropenia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • The Febrile Neutropenia epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2019 to 2032.
  • The Febrile Neutropenia epidemiology covered in the report provides historical as well as forecasted Febrile Neutropenia epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.
  • The Febrile Neutropenia report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
    The Febrile Neutropenia Epidemiology Report and Model provide an overview of the global trends of Febrile Neutropenia in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
    The report provides insight into the historical and forecasted patient pool of Febrile Neutropenia in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan

Systemic Mastocytosis Epidemiology Forecast Report 2019-2022 & 2032 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 17, 2022 - 1:26pm

The "Systemic Mastocytosis - Epidemiology Forecast to 2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Systemic Mastocytosis - Epidemiology Forecast to 2032" report has been added to ResearchAndMarkets.com's offering.
  • This "Systemic Mastocytosis - Epidemiology Forecast to 2032" report delivers an in-depth understanding of the disease, historical and forecasted Systemic Mastocytosis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • The Systemic Mastocytosis epidemiology covered in the report provides historical as well as forecasted Systemic Mastocytosis epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.
  • The Systemic Mastocytosis report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
    The Systemic Mastocytosis Epidemiology Report and Model provide an overview of the global trends of Systemic Mastocytosis in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
    The report provides insight into the historical and forecasted patient pool of Systemic Mastocytosis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan

Sofwave Medical Reports First Half Financial Results and Business Highlights

Retrieved on: 
Tuesday, August 16, 2022 - 1:30pm

SAN CLEMENTE, Calif., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, reported results for the first half of fiscal year 2022, for the period ended June 30, 2022.

Key Points: 
  • SAN CLEMENTE, Calif., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, reported results for the first half of fiscal year 2022, for the period ended June 30, 2022.
  • IFRS Operating Loss was $9.0M; Non-IFRS $6.3M
    Cash as of June 30, 2022 was $36M
    Mr. Louis Scafuri, Sofwave CEO commented, Sofwave significantly grew revenues 34% in the first half of 2022 while garnering industry accolades for SUPERB lifting and wrinkle reduction technology.
  • We are proud to have more than half of top ranking providers as users of Sofwaves SUPERB medical aesthetic devices.
  • With half of the remaining fiscal reporting period to go, we have also surpassed the number of Sofwave treatments performed for the whole of fiscal 2021.

Alopecia Epidemiology Forecasts Report 2019-2032 - Focus on United States, Germany, Spain, Italy, France, United Kingdom, and Japan - ResearchAndMarkets.com

Retrieved on: 
Friday, August 12, 2022 - 5:18pm

This "Alopecia - Epidemiology Forecast to 2032" report delivers an in-depth understanding of the disease, historical and forecasted Alopecia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Key Points: 
  • This "Alopecia - Epidemiology Forecast to 2032" report delivers an in-depth understanding of the disease, historical and forecasted Alopecia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • The Alopecia epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries.
  • The Alopecia epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM.
  • The Alopecia epidemiology covered in the report provides historical as well as forecasted Alopecia epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

Erosive Esophagitis Epidemiology Forecasts, 2032: Focus on 7MM - United States, Germany, Spain, Italy, France, United Kingdom, and Japan - ResearchAndMarkets.com

Retrieved on: 
Friday, August 12, 2022 - 5:19pm

This "Erosive Esophagitis - Epidemiology Forecast to 2032" report delivers an in-depth understanding of the disease, historical and forecasted Erosive Esophagitis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Key Points: 
  • This "Erosive Esophagitis - Epidemiology Forecast to 2032" report delivers an in-depth understanding of the disease, historical and forecasted Erosive Esophagitis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • The Erosive Esophagitis epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries.
  • The Erosive Esophagitis epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM.
  • The Erosive Esophagitis epidemiology covered in the report provides historical as well as forecasted Erosive Esophagitis epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

Humacyte Second Quarter 2022 Financial Results and Business Update

Retrieved on: 
Friday, August 12, 2022 - 12:00pm

-- Conference call and live webcast at 8:00 a.m. ET today –

Key Points: 
  • ET today
    DURHAM, N.C., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissues, complex tissue systems, and organs at commercial scale, today announced financial results for the second quarter ended June 30, 2022, and highlighted recent corporate accomplishments.
  • Early in the second quarter, Humacyte launched an initiative to provide its HAVs to hospitals in Ukraine for the treatment of wounded civilians and soldiers with vascular trauma injuries.
  • Revenue was $1.3 million for the second quarter of 2022, compared to $0.7 million for the second quarter of 2021, and was $1.5 million for the six months ended June 30, 2022, compared to $0.8 million for the six months ended June 30, 2021.
  • Other net income was $55.4 million for the second quarter of 2022, compared to $2.1 million for the second quarter of 2021, and was $57.3 million for the six months ended June 30, 2022, compared to $1.5 million for the six months ended June 30, 2021.

Acute Pancreatitis Epidemiology Analysis/Forecasts 2019-2021 & 2022-2032: Focus on United States, Germany, Spain, Italy, France, United Kingdom, and Japan - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 11, 2022 - 3:05pm

This "Acute Pancreatitis - Epidemiology Forecast to 2032" report delivers an in-depth understanding of the disease, historical and forecasted Acute Pancreatitis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Key Points: 
  • This "Acute Pancreatitis - Epidemiology Forecast to 2032" report delivers an in-depth understanding of the disease, historical and forecasted Acute Pancreatitis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • The Acute Pancreatitis epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries.
  • The Acute Pancreatitis epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM.
  • The Acute Pancreatitis epidemiology covered in the report provides historical as well as forecasted Acute Pancreatitis epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

H1 Launches AI-Powered and Evidence-Based Interactions to Meet the Evolving Needs of Pharmaceutical and Biotech Medical Affairs Teams

Retrieved on: 
Thursday, August 11, 2022 - 2:00pm

The role of Medical Affairs teams has shifted from specializing in products and diseases to being stewards of scientific discourse and outcomes-based information, said Ariel Katz, co-founder and CEO of H1.

Key Points: 
  • The role of Medical Affairs teams has shifted from specializing in products and diseases to being stewards of scientific discourse and outcomes-based information, said Ariel Katz, co-founder and CEO of H1.
  • Pharmaceutical and medical device companies can establish more efficient workflows, identify market signals that impact strategic decisions, and help medical field teams optimize every HCP engagement.
  • HCP Universe is built on the H1 Connect platform , which seamlessly blends H1 proprietary, public, industry, and self-reported HCP information and patient encounter data.
  • The H1 Connect platform democratizes access to HCP knowledge and groundbreaking insights for life sciences, academic medical institutions, health systems, and payors.